Social Media Ideas for Biopharmaceuticals

<![CDATA[Why Biologics R&D Platforms Are Failing Complex Modalities and What Must Change]]>

<![CDATA[Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTe...

<![CDATA[The Status of Nuvation Bio’s Pipeline]]>

Biopharma Hungry for GLP-1 Receptor Agonist Manufacturing Skills

NIBRT predicts that the market for GLP-1 receptor agonist-based diabetes and obesity meds will increase demand for biopharmaceutical engineers with a mix of synthetic chemistry and...

<![CDATA[CSPC Pharmaceutical & AstraZeneca Form Joint Venture for Biologics Manufacturing in China]]>

<![CDATA[What FDA's Peptide Decision Means for the Industry]]>

<![CDATA[What Would a Category One Designation Mean for Peptides?]]>

<![CDATA[Licensing Roundup: Biohaven & SK Biopharmaceuticals Enter Deal for BHV-7000, Haisco License’s Sentivera...

Bicistornic Vectors + piggyBac = Improved Antibody Cell Line Production

To produce stable cell lines for monoclonal antibody production, manufacturers typically use the piggyBac transposon system. For larger, multi-specific antibodies that have payload...

Celonic and Leukocare Collaborate to Support Complex Biologics and Advanced Drug Development

The collaboration brings together Celonic’s expertise in cell line development, drug substance process development, intensified bioprocessing, and GMP manufacturing with Leukocare’...

<![CDATA[Steer Bio Targets Lymphedema with Regenerative Cell Therapy Platform]]>

<![CDATA[Nuvation Bio’s Global Strategy]]>

The Multi-Attribute Method (MAM) as a Biologics Lifecycle Backbone

A more coherent approach: a peptide-mapping LC-HRMS (liquid chromatography-high resolution mass spectrometry) workflow that can identify and monitor multiple product quality attrib...

AI Protein Engineering Model Designed for Biomanufacturing

Generating biomanufacturing-relevant data on protein production in a large-scale, AI-enabled database is still rare. When commercialized, it may substantially improve development t...

Biocon sees stronger H2 on US biosimilar launches, regulatory easing

The US regulator’s decision to move away from subjecting companies to undertake mandatory efficacy trials in phase-3 bodes well for incumbents such as Biocon

Indiana Emerges as a Leading U.S. Biopharma Hub

Indiana has spent decades becoming a national leader in life sciences and pharmaceutical exports. Its strengths extend across universities, research institutes, manufacturers, supp...

End-to-end: Curia drives supply and scale for steroid and hormonal therapies

Explore how Curia tackles steroid manufacturing complexity, from early development to scaled, end-to-end commercial supply. The post End-to-end: Curia drives supply and scale for s...

<![CDATA[Pharmaceutical Executive Daily: Haisco Licenses Preclinical Immunology Asset to Sentivera]]>

Biopharma’s Drawdown Is a Chance to Build Biotech Back Better

American biotechnology hubs like Boston, Seattle, and San Diego are starting to wake up again. But will they be able to learn from the lessons of the recent past? The post Biopharm...

<![CDATA[Pharmaceutical Executive Daily: BioMarin and n-Lorem Foundation Enter Collaboration]]>

<![CDATA[Your Questions Answered: The Biggest Pharma and Biotech Stories This Week]]>

Advancing Microbial-Derived Biologics from Scale-Up to Commercial Production

In this GEN webinar, our expert speaker, Sam Zhang, PhD, will discuss emerging trends and capacity needs across the global late-stage microbial pipeline and CDMO landscape. The po...

In Vivo Protein Generation Using Nanoparticle Delivery: Emerging Platforms and CMC Strategies

In this GEN webinar, our expert speaker, Tao (Tony) Li, PhD, will discuss nanoparticle delivery opportunities beyond oncology and infectious disease, compare emerging nanocarrier p...

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...